NCT01149798已完成2 期
A Single Institutional Phase II Clinical Trial of Abraxane Combined With Cisplatin in Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 73
- 试验地点
- 1
- 主要终点
- Overall response rates (ORR) of abraxane and cisplatin combination therapy
研究概览
简要总结
This phase II trial on the assumption that abraxane and cisplatin combination therapy is efficacy in metastatic breast cancer.
详细描述
The rationales for the combination of Abraxane and cisplatin include that either drug has antitumor activity; they have different mechanisms; no cross-resistance are documented between them, and there have been some preclinical evidences indicating synergistic effects between the two agents. This phase II study will be undertaken to evaluate combination of cisplatin and weekly abraxane in terms of efficacy and safety in MBC patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subject must fulfill all of the following conditions or characteristics in order to be considered for study enrollment:
- •Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time without prejudice.
- •At least one measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST).
- •Histopathologically or cytologically confirmed breast cancer.
- •Female at an age of ≥18 years.
- •Prior taxane or platinum treatment allowed. However, the drug interval should be longer than 12 months in adjuvant/neo-adjuvant setting and three months in MBC patients who have obtained ORR with taxane- or platinum-containing regimens.
- •The lab values within 2 weeks prior to trial should meet:
- •PLT ≥100,000/mm3
- •ANC≥2000/mm3
- •Total bilirubin < upper limit of normal level（UNL, < 1.5 x UNL for patients with liver metastasis)
- •ALT/AST < 1.5 x UNL (< 2.5 x UNL for patients with liver metastasis)
- •AKP < 5 x UNL (except for patients with bone metastasis)
- •Serum creatinine < UNL
- •ECOG performance status of 0, 1 or
- •A life expectancy of more than 3 months.
排除标准
- •Pregnant or breast-feeding women.
- •Positive serum pregnancy test.
- •Unwilling to use a medically acceptable form of contraception, except for those who were surgically sterile or at least 1 year postmenopausal.
- •Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling.
- •Meningeal metastases.
- •Radiotherapy within the 4 weeks preceding study treatment start.
- •Incomplete recovery from the effects of major surgery.
- •Prior hormonal treatment allowed but must be discontinued 14 days prior to study entry.
- •Participation in any investigational drug study within 4 weeks preceding treatment start.
- •Blood transfusions or growth factors to aid hematological recovery within 2 weeks prior to study treatment start.
- •Significant medical condition that would make treatment or follow-up on this protocol difficult or problematic in the opinion of the treating oncologist.
- •Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer.
- •Serious uncontrolled intercurrent infections.
- •Poor compliance.
研究组 & 干预措施
Abraxane and Cisplatin combination
Experimental
Abraxane and Cisplatin combination
干预措施: Abraxane and Cisplatin combination (Drug)
结局指标
主要结局
Overall response rates (ORR) of abraxane and cisplatin combination therapy
时间窗: 2months
次要结局
- Progression free Suivial (PFS)(6 months)
- Number of adverse event(2 months)
- Overrall Survival (OS)(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II StudyMetastatic Malignant MelanomaNCT00462423Lynn E. Spitler, MD50
已完成
2 期
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung CancerNon-small Cell Lung CancerNCT00642759Massachusetts General Hospital36
尚未招募
2 期
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.Cervical CancerNCT06426056Peking University Third Hospital64
尚未招募
2 期
Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell Carcinoma (SCC)Resectable Oral and Oropharyngeal Squamous Cell CarcinomaRecurrent Oral and Oropharyngeal Squamous Cell CarcinomaNCT06728618Shanghai Zhongshan Hospital28
已完成
2 期
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial CancerNCT00006942National Cancer Institute (NCI)32